• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Esperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/11/25 8:02:26 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ESPR alert in real time by email
    espr-20250805
    TRUE000143486800014348682025-08-052025-08-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K/A
    (Amendment No. 1)

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): August 5, 2025

    Esperion Therapeutics, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3598626-1870780
    (State or other jurisdiction of
    incorporation)
    (Commission File Number)(I.R.S. Employer
    Identification No.)

    3891 Ranchero Drive, Suite 150
    Ann Arbor, MI
    (Address of principal executive offices)

    48108
    (Zip Code)

    Registrant’s telephone number, including area code: (734) 887-3903

    Not Applicable
    Former name or former address, if changed since last report

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading SymbolName of each exchange on which registered
    Common Stock, par value $0.001 per shareESPRNASDAQ Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

    Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐




    Explanatory Note

    Esperion Therapeutics, Inc. (the “Company”) is filing this Current Report on Form 8-K/A (this “Amendment No. 1”) to amend the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 5, 2025 (the “Original Form 8-K”) under Items 2.02 and 9.01, which announced its financial results for the three and six months ended June 30, 2025, as presented in a press release dated August 5, 2025, furnished as Exhibit 99.1 thereto (the “Earnings Release”). This Amendment No. 1 is being filed to correct certain disclosures in the Earnings Release contained in the tables entitled “Balance Sheet Data” for the period ended June 30, 2025 and “Statement of Operations” for the three and six months ended June 30, 2025, as well as the corresponding figures included in the narrative sections in the Earnings Release for the net income (loss) and net income (loss) per share for the three and six months ended June 30, 2025, and income from operations for the three months ended June 30, 2025, and to correct corresponding references made during the Company’s second quarter 2025 earnings call held on August 5, 2025. Other than the corrections discussed in this Amendment No. 1, as described in Item 2.02 herein, all other information disclosed in the Original Form 8-K, Earnings Release, and earnings call remains unchanged. A corrected version of the Earnings Release is furnished herewith as Exhibit 99.1.

    Item 2.02. Results of Operations and Financial Condition.

    On August 11, 2025, the Company furnished a press release announcing certain of its preliminary financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

    The Company has not yet completed its quarter-end financial close process for the quarter ended June 30, 2025. The preliminary financial data included in Exhibit 99.1 attached hereto has been prepared by, and is the responsibility of, the Company’s management, is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2025, is not a comprehensive statement of the Company’s financial results, and is subject to completion of the Company’s financial closing procedures. There can be no assurance that the Company’s actual financial results as of June 30, 2025 will not differ from these estimates, including as a result of the completion of the Company’s final adjustments, and other developments that may arise between the date of this filing and the time the Company’s financial results for such period are finalized, and any such changes could be material. These estimates should not be viewed as a substitute for interim financial statements prepared in accordance with accounting principles generally accepted in the United States and they are not necessarily indicative of the results to be achieved in any future period. Complete results as of June 30, 2025 will be included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Company assumes no duty to update these preliminary estimates, except as required by law.

    The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Any statements about the Company’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “continue,” and similar expressions, or the negative of these terms. These forward-looking statements include statements about the Company’s preliminary financial results. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and in any of the Company’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.





    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits
    Exhibit No.Description
    99.1
    Press Release dated August 11, 2025
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: August 11, 2025Esperion Therapeutics, Inc.
    By:/s/ Sheldon L. Koenig
    Sheldon L. Koenig
    President and Chief Executive Officer


    Get the next $ESPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESPR

    DatePrice TargetRatingAnalyst
    12/18/2024$4.00Neutral
    Goldman
    12/17/2024$8.00Overweight
    Cantor Fitzgerald
    6/20/2024$2.50Neutral → Underperform
    BofA Securities
    1/3/2024Buy → Neutral
    BofA Securities
    11/20/2023Neutral
    JP Morgan
    8/1/2023Under Perform → Market Perform
    Northland Capital
    6/15/2023$1.25 → $4.00Underperform → Buy
    BofA Securities
    3/16/2023$1.00Market Perform → Under Perform
    Northland Capital
    More analyst ratings

    $ESPR
    SEC Filings

    View All

    SEC Form S-8 filed by Esperion Therapeutics Inc.

    S-8 - Esperion Therapeutics, Inc. (0001434868) (Filer)

    8/13/25 4:18:43 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Esperion Therapeutics Inc.

    10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)

    8/13/25 4:07:43 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Esperion Therapeutics Inc.

    NT 10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)

    8/11/25 4:11:19 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Looker Benjamin sold $1,470 worth of shares (1,304 units at $1.13), decreasing direct ownership by 0.32% to 399,937 units (SEC Form 4)

    4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

    7/18/25 4:07:10 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Halladay Benjamin sold $12 worth of shares (11 units at $1.11), decreasing direct ownership by 0.00% to 474,462 units (SEC Form 4)

    4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

    7/18/25 4:05:21 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Thompson John Craig

    4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

    7/2/25 8:21:38 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HLS Therapeutics Announces Q2 2025 Financial Results

    Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's long-term debt totalling $8.5 millionExpanded cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion TherapeuticsTORONTO, Aug. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2025 ("Q2 2025" and "year-to-date"). All amounts are in thousands of United States ("U.S.") dollars u

    8/14/25 6:31:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares

    8/7/25 5:30:00 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

    – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the second quarter ended June 30, 2025, and provided a business

    8/5/25 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Esperion Therapeutics with a new price target

    Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00

    12/18/24 7:29:57 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Esperion Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $8.00

    12/17/24 7:45:32 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50

    6/20/24 7:33:38 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    Leadership Updates

    Live Leadership Updates

    View All

    Esperion Appoints Craig Thompson to Board of Directors

    ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel

    7/1/25 8:06:21 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

    – Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive

    4/24/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

    ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion's research and development strategy. Discussions will highlight Esperion's advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indicati

    4/10/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    Financials

    Live finance-specific insights

    View All

    HLS Therapeutics Announces Q2 2025 Financial Results

    Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's long-term debt totalling $8.5 millionExpanded cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion TherapeuticsTORONTO, Aug. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2025 ("Q2 2025" and "year-to-date"). All amounts are in thousands of United States ("U.S.") dollars u

    8/14/25 6:31:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

    – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the second quarter ended June 30, 2025, and provided a business

    8/5/25 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion to Report Second Quarter 2025 Financial Results on August 5

    ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical compan

    7/22/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ESPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

    SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

    11/14/24 8:42:21 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

    SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

    11/12/24 2:23:13 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

    SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

    11/4/24 1:33:59 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care